2025 annual financial data
Sutro Biopharma 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was -172.94%.
Operating income was -104,952,000 USD and net income was -191,086,000 USD.
Operating cash flow was -177,231,000 USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 102,484,000 USD
- Operating income
- -104,952,000 USD
- Net income
- -191,086,000 USD
- Operating cash flow
- -177,231,000 USD